NOTES

The use of Human Gonadotrophins of pituitary origin is a potential risk for Classical CJD. The use of human-derived products or the transfer of tissues (eggs or embryos) between individuals is a potential vCJD risk. Metrodin HP was withdrawn by the Committee on Safety of Medicines in the UK in 2003, as a precautionary measure against the possibility of the transmission of vCJD though products sourced from human urine. It was also withdrawn in Ireland in 2003. Other similar products have not been withdrawn. Human gonadotrophins of pituitary origin - Follicle Stimulating Hormone (FSH) and Luetinizing hormone (LH) were never used in the Republic of Ireland. These gonadotrophins were used in the UK but not after 1986. The situation in other countries varied so specific dates cannot be given

ACCEPT

• Donors who have received recombinant hormone therapy as part of a course of IVF (In Vitro Fertilisation) as long as treatment concluded at least 3 months ago and the donor is not pregnant
• If the donor received donated sperm, but exclude pregnancy
• Donors who received infertility treatment by injection in ROI or UK since 1st December 2003 as long as treatment concluded at least 3 months ago and the donor is not pregnant
• If the donor cannot confirm if Metrodin HP was used. There is no requirement to refer a donor to a Specialist Medical Officer for Medical follow up

 DEFER

• If currently undergoing investigations for infertility
• For three months following conclusion of treatment with Clomid /Clomifial or other oral medications, but exclude pregnancy
• For three months following IVF treatment in ROI / UK if otherwise eligible (see below) but exclude pregnancy

 DEFER AND REFER:

• To a Specialist Medical Officer any donor who had infertility treatment outside of ROI / UK until clarification is received from their GP / Consultant regarding eligibility to donate
• To a Specialist Medical Officer any donor who had treatment by injection for infertility between 1956 – 1986 in the UK until clarification is received from their GP / Consultant regarding eligibility to donate

 PERMANENTLY EXCLUDE:

• Recipients of Human Gonadotrophin of pituitary origin. This treatment would have been by injection
• If the donor received a donated egg or embryo (including as a surrogate) since 1st January 1980
• A donor that can confirm that they were treated with Metrodin HP. This would have been before 1 December 2003

ADDITIONAL INFORMATION

 The use of Human Gonadotrophins of pituitary origin is a potential risk for Classical CJD

The use of human-derived products or the transfer of tissues (eggs or embryos) between individuals is a potential vCJD risk. Metrodin HP was withdrawn by the Committee on Safety of Medicines in the UK in 2003, as a precautionary measure against the possibility of the transmission of vCJD though products sourced from human urine. It was also withdrawn in Ireland in 2003. Other similar products have not been withdrawn. Human gonadotrophins of pituitary origin - Follicle Stimulating Hormone (FSH) and Luetinizing hormone (LH) were never used in the Republic of Ireland. These gonadotrophins were used in the UK but not after 1986. The situation in other countries varied so specific dates cannot be given

SEE IF RELEVANT

• HRT